Stock Events

Stock Events

Elicio Therapeutics 

$10.65
31
+$0.05+0.52% Today

Statistics

Day High
10.69
Day Low
10.29
52W High
13.84
52W Low
4.96
Volume
234,757
Avg. Volume
-
Mkt Cap
186.17M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.39
-1.08
-0.76
-0.45
Expected EPS
-0.465
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-103.8MNet Income

Analyst Ratings

18Average Price Target
The highest estimate is 20.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ELTX. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap17.99B
Moderna Inc. focuses on mRNA-based therapies, including cancer vaccines, directly competing with Elicio's amphiphile technology in cancer immunotherapy.
BioNTech
BNTX
Mkt Cap24.67B
BioNTech SE develops targeted cancer therapies using mRNA, similar to Elicio's approach in stimulating robust immune responses against cancer.
Novavax
NVAX
Mkt Cap1.32B
Novavax, Inc. is involved in the development of vaccines, including for cancer, which competes with Elicio's cancer vaccine platforms.
Gilead Sciences
GILD
Mkt Cap163.4B
Gilead Sciences, Inc. has a strong portfolio in oncology and cell therapy, areas where Elicio is also trying to make an impact.
AMGEN
AMGN
Mkt Cap178B
Amgen Inc. works on innovative therapeutics in oncology, including immune-oncology, a field where Elicio is also active.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol-Myers Squibb Company offers immunotherapy treatments for cancer, competing with Elicio's cancer immunotherapies.
Merck
MRK
Mkt Cap277.02B
Merck & Co., Inc. is a leader in cancer immunotherapy with products like Keytruda, competing in the same space as Elicio's therapies.
Pfizer
PFE
Mkt Cap149.77B
Pfizer Inc. develops and markets drugs and vaccines, including cancer treatments, which overlaps with Elicio's therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap73.54B
Regeneron Pharmaceuticals, Inc. is known for its innovative biopharmaceuticals targeting various diseases, including cancer, similar to Elicio's focus.
Novartis
NVS
Mkt Cap279.67B
Novartis AG has a broad focus in healthcare, including advanced therapies in oncology, competing with Elicio's cancer treatment technologies.

About

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Show more...
CEO
Mr. Robert T. Connelly
Employees
32
Country
United States
ISIN
US28657F1030

Listings

MU
DE
9HA.MU
STU
DE
9HA.STU
F
DE
9HA.F
XNAS
US
ELTX

0 Comments

Share your thoughts

FAQ

What is Elicio Therapeutics stock price today?▼
The current price of ELTX is $10.65 USD — it has increased by +0.52% in the past 24 hours. Watch Elicio Therapeutics stock price performance more closely on the chart.
What is Elicio Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Elicio Therapeutics stocks are traded under the ticker ELTX.
Is Elicio Therapeutics stock price growing?▼
ELTX stock has risen by +3.15% compared to the previous week, the month change is a -0.23% fall, over the last year Elicio Therapeutics has showed a +107.5% increase.
What is Elicio Therapeutics market cap?▼
Today Elicio Therapeutics has the market capitalization of 186.17M
When is the next Elicio Therapeutics earnings date?▼
Elicio Therapeutics is going to release the next earnings report on May 20, 2026.
What were Elicio Therapeutics earnings last quarter?▼
ELTX earnings for the last quarter are -0.45 USD per share, whereas the estimation was -0.45 USD resulting in a -1.12% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Elicio Therapeutics revenue for the last year?▼
Elicio Therapeutics revenue for the last year amounts to 0 USD.
What is Elicio Therapeutics net income for the last year?▼
ELTX net income for the last year is -103.8M USD.
How many employees does Elicio Therapeutics have?▼
As of May 06, 2026, the company has 32 employees.
In which sector is Elicio Therapeutics located?▼
Elicio Therapeutics operates in the Health & Wellness sector.
When did Elicio Therapeutics complete a stock split?▼
Elicio Therapeutics has not had any recent stock splits.
Where is Elicio Therapeutics headquartered?▼
Elicio Therapeutics is headquartered in Boston, United States.